Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial | Zendy

Yves Dauvilliers | Zendy; Colin M. Shapiro | Zendy; Geert Mayer | Zendy; Gert Jan Lammers | Zendy; Hélène A. Emsellem | Zendy; Giuseppe Plazzi | Zendy; Dan Chen | Zendy; Lawrence P. Carter | Zendy; Lawrence Lee | Zendy; Jed Black | Zendy; Michael J. Thorpy | Zendy

Open Access

Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial

Author(s) -

Yves Dauvilliers,

Colin M. Shapiro,

Geert Mayer,

Gert Jan Lammers,

Hélène A. Emsellem,

Giuseppe Plazzi,

Dan Chen,

Lawrence P. Carter,

Lawrence Lee,

Jed Black,

Michael J. Thorpy

Publication year - 2020

Publication title -

cns drugs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.565

H-Index - 108

eISSN - 1179-1934

pISSN - 1172-7047

DOI - 10.1007/s40263-020-00744-2

Subject(s) - cataplexy , narcolepsy , epworth sleepiness scale , placebo , subgroup analysis , excessive daytime sleepiness , psychology , modafinil , anesthesia , medicine , sleep disorder , confidence interval , psychiatry , polysomnography , insomnia , apnea , alternative medicine , pathology

Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, improved wakefulness and reduced excessive daytime sleepiness (EDS) in studies of participants with narcolepsy with and without cataplexy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research